Roche to acquire Dutalys

Roche (SIX:ROG; OTCQX:RHHBY) will acquire antibody developer Dutalys GmbH (Vienna, Austria) for $133.8 million in cash up front. Dutalys' shareholders are eligible for $355 million in undisclosed milestones.

Roche intends to use Dutalys' DutaMab technology to develop human bi-specific and tetra-specific antibodies across a range of undisclosed therapeutic areas. Roche will integrate Dutalys into its large molecule research unit. ...